Beckman Coulter
to Utilize the ALZpath pTau217 Antibody to Detect Key Biomarker for
Alzheimer's Disease on its DxI 9000 Immunoassay
Analyzer
CARLSBAD, Calif., July 15,
2024 /PRNewswire/ -- ALZpath, Inc., a leading
developer of innovative diagnostic tools and solutions for
Alzheimer's disease and related dementias, announced today that it
has signed a licensing agreement with Beckman Coulter Diagnostics,
a global leader in clinical diagnostics, for use of its
best-in-class ALZpath pTau217 antibody in a blood-based in vitro
diagnostic (IVD) test on its DxI 9000 Immunoassay Analyzer to
advance Alzheimer's disease diagnosis.
The proprietary ALZpath pTau217 antibody, used in blood-based
assays, has displayed high diagnostic accuracy, sensitivity, and
reliability in detecting the presence and progression of
Alzheimer's disease – a critical need for clinicians and
researchers as new treatments become more widely available to
patients.
"Alzheimer's disease affects tens of millions of people
worldwide, but many remain undiagnosed and are consequently unable
to be identified for clinical trials or get access to emerging
treatments," said Chad Holland, CEO
and president at ALZpath. "Collaborating with Beckman Coulter to integrate our pTau217
antibody into a highly accurate blood-based test run on their DxI
9000 analyzers will significantly expand access to precise testing
and early diagnosis for patients around the world."
Blood-based assays, utilizing the ALZpath pTau217 antibody, have
demonstrated similar diagnostic accuracy as traditional methods,
such as PET imaging and cerebral spinal fluid (CSF) testing, but
with the accessibility and affordability of a simple, less invasive
blood test that can be administered in a variety of clinical
settings.
"We recognize the critical need for more sensitive, precise, and
scalable diagnostic testing for Alzheimer's disease," added
Kathleen Orland, senior vice
president, general manager, Chemistry, and Immunoassay for Beckman
Coulter Diagnostics. "We selected ALZpath's pTau217 antibody
following rigorous evaluation due to its high performance in
detecting amyloid pathology and ability to integrate into our
advanced DxI 9000 platform to support broad-based testing. We are
excited about the combination of ALZpath and Beckman Coulter innovations coming together to
develop a new fully automated, high throughput, blood-based
Alzheimer's disease test for the millions of patients who suffer
from dementia worldwide."
Globally available, the DxI 9000 Immunoassay Analyzer is
Beckman Coulter's next generation
immunoassay platform featuring the proprietary Lumi-Phos PRO
substrate that enables development of clinically relevant, high
sensitivity assays to support evolving healthcare needs. The DxI
9000 Analyzer combines this high sensitivity with market leading
core laboratory throughput, reliability, reproducibility, quality,
and an extensive core menu.
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools
and solutions for Alzheimer's disease and related dementias. The
novel ALZpath pTau217 antibody, integral to the most advanced,
widely available blood-based tests to detect Alzheimer's disease,
is transforming its diagnosis and treatment monitoring, providing
accurate and accessible tools for researchers and healthcare
professionals worldwide. To help millions of patients in need,
ALZpath democratizes access to its proprietary robust antibody,
which is used by researchers, clinicians, and industry partners
around the world to accelerate the discovery of new treatments and
improve patient care.
To learn more about the company, please visit
https://alzpath.bio/ and follow us on LinkedIn.
ALZpath Media Contact:
Nechama Rosengarten
FINN Partners
nechama.rosengarten@finnpartners.com
View original
content:https://www.prnewswire.com/news-releases/alzpath-signs-licensing-agreement-with-beckman-coulter-diagnostics-to-provide-proprietary-ptau217-antibody-to-develop-a-diagnostic-blood-test-for-alzheimers-disease-302196639.html
SOURCE ALZpath, Inc.